Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

7.260 -0.430 (-5.59%)
Streaming Delayed Price Updated: 3:27 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700... 
Via Benzinga
What's Going On With SciSparc Ltd Stock?
SciSparc Ltd. (NASDAQ: SPRC) shares are trading higher Wednesday. 
Via Benzinga
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
Why SciSparc Ltd Stock Is Blasting Higher
SciSparc Ltd. 
Via Benzinga
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
Why Is Clearmind Medicine (CMND) Stock Up 50% Today?
Psychedelic-medicine specialist Clearmind Medicine posted encouraging study results, leading to a significant boost in CMND stock. 
Via InvestorPlace
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment  
Via Benzinga
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc Adopts Limited Duration Shareholder Rights Plan
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
From SciSparc Ltd
Via GlobeNewswire
EXCLUSIVE: Clearmind Medicine's Psychedelic-Based Treatment Shows Encouraging Preclinical Activity In Obesity, Metabolic Disorders
Clearmind Medicine Inc (NASDAQ: CMND) has released results from its pre-clinical trial of the combination therapy. 
Via Benzinga
What's Going On With SciSparc Shares Today?
SciSparc Ltd (NASDAQ: SPRC) shares are trading lower Monday. The company announced results for MitoCareX Bio with its drug discovery platform. 
Via Benzinga
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc, Deere & Company, Baidu, Marathon Digital, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks showed a positive trend on Wednesday. The Dow Jones index rose by approximately 184 points, marking an increase of 0.5% to 35,273.03. 
Via Benzinga
Topics Stocks
Gold Moves Lower; SciSparc Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 175 points on Wednesday. The Dow traded up 0.50% to 35,265 while the NASDAQ rose 0.66% to 14,293.93. The S&P... 
Via Benzinga
Topics Stocks
Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter financial results. 
Via Benzinga
Crude Oil Falls Sharply; Deere Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Wednesday. The Dow traded up 0.51% to 35,266.35 while the NASDAQ rose 0.59% to 14,284.26. The... 
Via Benzinga
Topics Stocks
Why Is PaxMedica (PXMD) Stock Up 57% Today?
PaxMedica stock is heading higher on Wednesday as a public offering for shares of PXMD closes and the company's shares see heavy trading. 
Via InvestorPlace
Cannabis Market Evolves In Israel Amid War With Hamas, New Merger On The Horizon
Over the years, Israel has grown into an international giant in the cannabis industry. 
Via Benzinga
Topics Cannabis
Why Is SciSparc (SPRC) Stock Up 20% Today?
SciSparc stock is rising higher on Wednesday as SPRC investors react to the company announcing plans for a merger after a strategic review. 
Via InvestorPlace
Dow Surges 150 Points; US Jobless Claims Decline Sharply
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 150 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.43% to 35,239.40 while the NASDAQ... 
Via Benzinga
Topics Stocks
Why SciSparc Stock Is Trading Higher Wednesday
SciSparc Ltd (NASDAQ: SPRC) shares are trading higher Wednesday after the company signed a non-binding letter of intent to merge with a  
Via Benzinga
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. 
Via Benzinga
Why SciSparc Ltd Stock Is Lighting Up
SciSparc Ltd (NASDAQ: SPRC) shares are trading higher Wednesday after the company announced positive results from the Phase IIa clinical trial of its investigational compound for the 
Via Benzinga
Why Is SciSparc (SPRC) Stock Up 47% Today?
SciSparc stock is rising higher with heavy trading of SPRC shares as investors celebrate positive clinical trial results. 
Via InvestorPlace
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
From SciSparc Ltd
Via GlobeNewswire
FDA-Approved Synthetic THC Trials Show 21% Tic Reduction In Tourette Syndrome Patients
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment. 
Via Benzinga
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.